Dianthus Therapeutics (DNTH) Price & Analysis

Compare

403 Followers

DNTH Stock Chart & Stats

$42.13

$0.37(1.44%)

At close: Jan 08 4:00 PM EST

$42.13

$0.37(1.44%)

Day’s Range― - ―

52-Week Range$13.37 - $45.46

Previous CloseN/A

Volume29.07K

Average Volume (3M)1.00M

Market Cap

$1.32B

Enterprise Value$411.31M

Total Cash (Recent Filing)$402.61M

Total Debt (Recent Filing)$1.28M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Mar 19, 2026

EPS Estimate

-1.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding39,816,223

10 Day Avg. Volume588,847

30 Day Avg. Volume1,003,841

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)2.06

Price to Sales (P/S)116.48

P/FCF Ratio-9.28

Enterprise Value/Market Cap0.31

Enterprise Value/Revenue133.63

Enterprise Value/Gross Profit133.63

Enterprise Value/Ebitda-3.01

Forecast

1Y Price Target

$70.63

Price Target Upside67.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe Phase 3 CAPTIVATE study is enrolling faster than expected, with interim analysis now expected earlier than initially planned.

Financial OutlookDianthus Therapeutics has approximately $525 million in adjusted cash, cash equivalents, and investments, which are expected to fund operations into 2028.

Pipeline DevelopmentRecent results from the Phase II MaGic study showed robust improvements in patients after receiving claseprubart, indicating potential efficacy.

Bears Say

Clinical ChallengesThere are questions on dose selection in Phase III for gMG, particularly the proposed 300 mg Q4W arm alongside the Q2W option.

Financial PerformanceFor 3Q25, Dianthus reported a net loss of $0.97 per share, which was higher than the consensus estimate of a $0.87 loss per share.

Investor SentimentShort interest for Dianthus Therapeutics' stock is relatively high at 12.3% of the float, indicating potential skepticism or bearish sentiment from investors.

Dianthus Therapeutics News

Dianthus price target raised to $47 from $40 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Dianthus (DNTH) to $47 from $40 and keeps a Buy...

1M ago

DNTH

Dianthus Therapeutics: Strong Financials and Promising Clinical Developments Justify Buy Rating

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Dianthus Therapeutics, retaining the price target of...

1M ago

DNTH

Dianthus price target raised to $62 from $60 at Oppenheimer

Oppenheimer analyst Trevor Allred raised the firm’s price target on Dianthus (DNTH) to $62 from $60 and keeps...

1M ago

SNY

DNTH

Dianthus Therapeutics Reports Q3 2025 Financial Results

Dianthus Therapeutics, Inc. ( ($DNTH) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

DNTH

Dianthus Therapeutics: Promising Pipeline and Strong Financials Justify Buy Rating

TD Cowen analyst Yaron Werber has maintained their bullish stance on DNTH stock, giving a Buy rating yesterday....

1M ago

DNTH

Dianthus reports Q3 EPS (97c), consensus (90c)

Reports Q3 revenue $396,000, consensus $523.640. “I’m extremely proud of our team’s outstanding track record of execution against...

1M ago

DNTH

Dianthus Therapeutics Reports Positive Phase 2 Results

Dianthus Therapeutics ( ($DNTH) ) just unveiled an announcement. On November 3, 2025, Dianthus Therapeutics updated its corporate...

1M ago

DNTH

Promising Clinical Data and Strategic Plans Position Dianthus Therapeutics as an Attractive Investment Opportunity

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target...

1M ago

DNTH

Dianthus Therapeutics Advances CIDP Treatment with DNTH103 Study

Dianthus Therapeutics, Inc. (($DNTH)) announced an update on their ongoing clinical study. Study Overview: Dianthus Therapeutics, Inc. is...

2M ago

DNTH

Dianthus Therapeutics Advances Phase 2 Study of DNTH103 for Neuropathy

Dianthus Therapeutics, Inc. (($DNTH)) announced an update on their ongoing clinical study. Study Overview: Dianthus Therapeutics, Inc. is...

2M ago

DNTH

Dianthus Therapeutics: Strategic Positioning and Innovative Pipeline Justify Buy Rating

William Blair analyst Myles Minter has reiterated their bullish stance on DNTH stock, giving a Buy rating today....

2M ago

DNTH

Dianthus Therapeutics’ Strategic Moves and Pipeline Potential Justify Buy Rating

Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Dianthus Therapeutics. The associated price target...

2M ago

DNTH

Dianthus Therapeutics Signs License Agreement with Nanjing Leads

Dianthus Therapeutics ( ($DNTH) ) has shared an announcement. On October 16, 2025, Dianthus Therapeutics entered into a...

2M ago

DNTH

Dianthus enters exclusive license agreement with Leads Biolabs for DNTH212

Dianthus (DNTH) Therapeutics entered into an exclusive licensing agreement with Nanjing Leads Biolabs for DNTH212, a first and...

2M ago

DNTH

DNTH FAQ

What was Dianthus Therapeutics’s price range in the past 12 months?

Dianthus Therapeutics lowest stock price was $13.37 and its highest was $45.45 in the past 12 months.

What is Dianthus Therapeutics’s market cap?

Dianthus Therapeutics’s market cap is $1.32B.

When is Dianthus Therapeutics’s upcoming earnings report date?

Dianthus Therapeutics’s upcoming earnings report date is Mar 19, 2026 which is in 96 days.

How were Dianthus Therapeutics’s earnings last quarter?

Dianthus Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.97 earnings per share for the quarter, missing the consensus estimate of -$0.867 by -$0.103.

Is Dianthus Therapeutics overvalued?

According to Wall Street analysts Dianthus Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Dianthus Therapeutics pay dividends?

Dianthus Therapeutics does not currently pay dividends.

What is Dianthus Therapeutics’s EPS estimate?

Dianthus Therapeutics’s EPS estimate is -1.07.

How many shares outstanding does Dianthus Therapeutics have?

Dianthus Therapeutics has 39,816,223 shares outstanding.

What happened to Dianthus Therapeutics’s price movement after its last earnings report?

Dianthus Therapeutics reported an EPS of -$0.97 in its last earnings report, missing expectations of -$0.867. Following the earnings report the stock price went up 8.005%.

Which hedge fund is a major shareholder of Dianthus Therapeutics?

Currently, no hedge funds are holding shares in DNTH

Dianthus Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-28.57%

Trailing 12-Months

Asset Growth

-11.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Dianthus Therapeutics

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Dianthus Therapeutics (DNTH) Earnings & Revenues

Historic Earnings Reports

DNTH Stock 12 Month Forecast

Average Price Target

$70.63

▲(67.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","58":"$58","101":"$101","36.5":"$36.5","79.5":"$79.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$70.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":47,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$47.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,36.5,58,79.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.2,47.56923076923077,51.93846153846154,56.30769230769231,60.676923076923075,65.04615384615384,69.41538461538462,73.78461538461539,78.15384615384616,82.52307692307693,86.8923076923077,91.26153846153846,95.63076923076923,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.2,45.31,47.42,49.53,51.64,53.75,55.86,57.97,60.08,62.19,64.3,66.41,68.52,{"y":70.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.2,43.4923076923077,43.784615384615385,44.07692307692308,44.36923076923077,44.66153846153846,44.95384615384616,45.246153846153845,45.53846153846154,45.830769230769235,46.12307692307692,46.41538461538462,46.707692307692305,{"y":47,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.15,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.83,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >